Latrunculin A 产品活性：Latrunculin A (LAT-A) 是一种 G-肌动蛋白聚合 (G-actin polymerization) 抑制剂，在红海海绵 Latrunculia magnifica 中发现的。Latrunculin A 能够与肌动蛋白 (actin) 单体结合，抑制其聚集，对 ATP-actin，ADP-Pi-actin，ADP-actin 和 G-actin 的 Kd 值分别为 0.1，0.4，4.7 μM 和 0.19 μM。Latrunculin A 具有有效的抗转移特性，可用于癌症的研究。Latrunculin A 抑制细胞迁移。 产品来源： https://www.medchemexpress.cn/latrunculin-a.html 研究领域：Cytoskeleton 作用靶点：Arp2/3 Complex 结构分类：抗生素 | 疾病研究 | 抗癌 | 抗生素 | 大环内脂类 | 结构分类 In Vitro: Latrunculin A (50-1000 nM) exhibits potent anti-invasive activity against human prostate cancer PC-3M cells, inhibits PC-3M-CT+ spheroids disaggregation and cell migration.? Latrunculin A (3-30 μM) inhibits hypoxia-induced HIF-1 activation with an IC50 value of 6.7 μM in human breast carcinoma T47D cells.? Latrunculin A (0-0.2 μM, 4 hours) has a significant inhibitory effect on HuR levels at high concentrations such as 0.2 μM in human hepatoma HepG2 cells while inhibits HuR only at 0.02 μM but no inhibitory effect at high concentrations in human hepatoma Huh7 cells.? Latrunculin A (0.1 μM, 24 hours) can lead to a significant decrease in cell migration and has an inhibitory effect on cell proliferation in human hepatoma cell lines HepG2. In Vivo: Latrunculin A (intraperitoneal injection, 0.05 mg/kg, three doses in the first 20 days, 120 days) has strong antitumor effect in male BALB/c nude mice models infected with adenocarcinoma (MKN45) or carcinoma (NUGC-4). 相关产品：Cytochalasin B | Cytochalasin D | CK-666 | SMIFH2 | Jasplakinolide | Benproperine phosphate | CK-636 | Phalloidin-TRITC | CK-869 | Wiskostatin | EG-011 | 187-1, N-WASP inhibitor | Phallacidin | Fequesetide | 19-O-Acetylchaetoglobosin A | Dihydrocytochalasin B 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。